Savient Pharmaceuticals, Inc. (Savient) is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union.
KRYSTEXXA was approved for marketing by the United States Food and Drug Administration (FDA) on September 14, 2010 and became commercially available in the United States by prescription on December 1, 2010. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. As of March 1, 2011, the Company operated within one segment, which included sales of KRYSTEXXA, Oxandrin and oxandrolone and the research and development activities of KRYSTEXXA. KRYSTEXXA is indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.
Address
Key stats and ratios
|
| Net profit margin | -521.01% | -656.45% |
| Operating margin | -429.41% | -539.85% |
| EBITD margin | - | -658.33% |
| Return on average assets | -93.71% | -74.80% |
| Return on average equity | - | - |
| Employees | 122 | - |
|
|
|
No comments:
Post a Comment